Skip to main content Accessibility help

Cost comparison of two surgical strategies in the treatment of breast cancer: Sentinel lymph node biopsy versus axillary lymph node dissection

  • Lionel Perrier (a1), Karima Nessah (a1), Magali Morelle (a1), Hervé Mignotte (a1), Marie-Odile Carrère (a1) and Alain Brémond (a1)...


Objectives: The feasibility and accuracy of sentinel lymph node biopsy (SLNB) in the treatment of breast cancer is widely acknowledged today. The aim of our study was to compare the hospital-related costs of this strategy with those of conventional axillary lymph node dissection (ALND).

Methods: A retrospective study was carried out to determine the total direct medical costs for each of the two medical strategies. Two patient samples (n=43 for ALND; n=48 for SLNB) were selected at random among breast cancer patients at the Centre Léon Bérard, a comprehensive cancer treatment center in Lyon, France. Costs related to ALND carried out after SLNB (either immediately or at a later date) were included in SLNB costs (n=18 of 48 patients).

Results: Total direct medical costs were significantly different in the two groups (median 1,965.86€ versus 1,429.93€, p=0.0076, Mann-Whitney U-test). The total cost for SLNB decreased even further for patients who underwent SLNB alone (median, 1,301€). Despite the high cost of anatomic pathology examinations and nuclear medicine (both favorable to ALND), the difference in direct medical costs for the two strategies was primarily due to the length of hospitalization, which differs significantly depending on the technique used (9-day median for ALND versus 3 days for SLNB, p<0.0001).

Conclusions: A lower morbidity rate is favorable to the generalization of SLNB, when the patient's clinical state allows for it. From an economic point of view, SLNB also seems to be preferred, particularly because our results confirm those found in two published studies concerning the cost of SLNB.



Hide All
Agence Nationale d'Accréditation en Santé. 2002. La technique du ganglion sentinelle dans le cancer du sein. Evidence based recommendation (ISBN: 2-914517-23-8). Paris: ANAES
Albertini JJ, Lyman GH, Cox CE, et al. 1996 Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 276: 18181822.
Chirikos TN, Berman CG, Luther SL, Clark RA. 2001 Cost consequences of sentinel lymph node biopsy in the treatment of cancer. A preliminary analysis. Int J Technol Assess Health Care. 17: 626631.
Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. 1997. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press
Gemignani ML, Cody HS, Fey JV, et al. 2000 Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer. Ann Surg Oncol. 7: 575580.
Giuliano AE, Haigh PI, Brennan MB, et al. 2000 Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 18: 25532559.
Leibenstein H. 1966 Allocative efficiency vs X-efficiency. Am Econ Rev. 56: 392415.
Philip T. 1996 The Léon Bérard cancer center. Pediatr Hemat Oncol. 13: 477486.
Pressman P. 1998 Surgical treatment and lymphedema. Cancer. 83: 27822787.
Schwartz GF, Giuliano AE, Veronesi U. 2002 Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast April 19 to 22, 2001 Philadelphia, Pennsylvania. Cancer. 94: 25422551.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed